Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia

Inclusion Criteria: * Patients with Acute Myeloid Leukemia in first relapse with first response duration \> 9 months. * Age between 18 and 65 years. * Treatment with hydroxyurea or purinethol is allowed if discontinued at least 24 hours before the start of study treatment. * White blood count less than 30 x 109/L * Left ventricular ejection fraction more than 50% on echocardiography or multigated acquisition scan or similar radionuclide angiographic scan. * Total bilirubin less than 1.5 x upper limit of normal= ULN or AST and ALT less than 2.5 x ULN or gammaGT less than 2.5 x ULN. * Serum creatinine less than 1.5 x ULN and/or creatinine clearance more than 50 ml/mn. * ECOG performance status less than 2 * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. * Absence of pregnancy or lactation * Affiliated to French social security system or similar * Signed informed consent Exclusion Criteria: * AML evolving from MPD and/or secondary AML * Patients treated with more than 270 mg/m2 of daunorubicin during first line therapy. * Have any of the following within the last 9 months : * Unstable supraventricular arrhythmia or patient with a pace-maker * Any ventricular arrhythmia * Congestive heart failure * Myocardial infarction, ischemia, stable coronary disease or angina pectoris * Syncope with a known cardiovascular etiology * Known hypersensitivity or contra-indication to drugs used in the protocol = G-CSF, daunorubicin, cytarabine or to excipients. * Previous treatment with plerixafor. * Previous hematopoietic stem cell transplantation = Allologous or autologous. * White blood count more than 30 x 109/L despite treatment with hydroxyurea or purinethol. * Treatment with chemotherapy or G-CSF within 3 months of screening. * Uncontrolled active infection. * Uncontrolled arrythmia * Grade more than 3 renal dysfunction with serum creatinine more than 1.5 x ULN and/or creatinine clearance less than 50 ml/mn. * Significant neurologic grade more than 2 or psychiatric disorder, dementia or seizures. * Clinical symptoms suggesting active central nervous system leukemia. * Pre-existing disorder predisposing the patient to serious or life-threatening infections = cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder or cytopenia * Thrombocytopenia refractory to platelet transfusion * Anticoagulant therapy * Severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock or disseminated intravascular coagulation. * Thrombocytopenia refractory to platelet transfusion. * Prior total body irradiation more than 10 Gy. * Known HIV, Hepatitis B or C positivity. * Participation into a clinical study of an investigational agent within 14 days before study entry. * Pregnancy or breastfeeding * Adult patient protected by law * Concurrent treatment with any other anti-cancer therapy except hydroxyurea